Future Directions in Metastatic Triple-Negative Breast Cancer Care

This video was supported by Gilead Sciences, Inc., but editorially independently created by the Oncology Nursing News team.

NP Theresa Stukus and NP Nelli Zafman conclude the discussion by reflecting on the resources, practice changes, and multidisciplinary strategies needed to successfully implement advances in the frontline management of metastatic triple-negative breast cancer (mTNBC). The faculty emphasize that integrating antibody-drug conjugates (ADCs) into routine practice requires more than understanding emerging clinical data; it also depends on consistent patient education, proactive adverse event management, and strong collaboration across the multidisciplinary care team. They summarize key clinical takeaways for oncology advanced practice providers, highlighting the importance of individualized treatment selection, early toxicity recognition, patient engagement, and ongoing communication to optimize outcomes. Looking ahead, NP Stukus and NP Zafman discuss remaining evidence gaps, particularly the need to better define optimal treatment sequencing as additional therapies become available. They conclude by reinforcing the evolving role of APPs in translating new evidence into clinical practice while supporting patients throughout their metastatic triple-negative breast cancer treatment journey.